A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)

This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa. Participants will undergo assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period. The study aims to evaluate whether differences in prophylactic therapy are associated with differences in bone health outcomes.

NCT Number	NCT07582276
Lead Sponsor	Arkansas Children's Hospital Research Institute Collaborators: Genzyme, a Sanofi Company
Conditions	Hemophilia a
Enrollment	50 participants
Start Date	2026-07-01
Primary Completion	2031-08-01 (estimated)
Study Completion	2032-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-04